SpringWorks Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Public

  • Employees
  • 305

Employees

  • Stock Symbol
  • SWTX

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $34.01
  • (As of Friday Closing)

SpringWorks Therapeutics General Information

Description

SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing highly prevalent, genetically defined cancers.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 100 Washington Boulevard
  • Stamford, CT 06902
  • United States
+1 (203)
Primary Industry
Drug Discovery
Other Industries
Discovery Tools (Healthcare)
Biotechnology
Stock Exchange
NAS
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • 100 Washington Boulevard
  • Stamford, CT 06902
  • United States
+1 (203)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SpringWorks Therapeutics Stock Performance

As of 08-Nov-2024, SpringWorks Therapeutics’s stock price is $34.01. Its current market cap is $2.52B with 74.3M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$34.01 $33.09 $18.00 - $53.92 $2.52B 74.3M 864K -$4.44

SpringWorks Therapeutics Financials Summary

As of 30-Jun-2024, SpringWorks Therapeutics has a trailing 12-month revenue of $86.2M.

In Thousands,
USD
TTM 30-Jun-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 2,360,815 2,267,080 976,353 2,626,178
Revenue 86,186 5,447 0 0
EBITDA (324,072) (346,384) (282,799) (173,966)
Net Income (301,063) (325,104) (277,417) (173,910)
Total Assets 617,331 725,788 630,242 452,494
Total Debt 7,059 7,057 5,251 1,291
Public Fundamental Data provided by Morningstar, Inc. disclaimer

SpringWorks Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore SpringWorks Therapeutics‘s full profile, request access.

Request a free trial

SpringWorks Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
SpringWorks Therapeutics Inc is a clinical stage biopharmaceutical company applying a precision medicine approach to acq
Drug Discovery
Stamford, CT
305 As of 2023

San Diego, CA
 

New York, NY
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

SpringWorks Therapeutics Competitors (98)

One of SpringWorks Therapeutics’s 98 competitors is Travere Therapeutics, a Formerly VC-backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Travere Therapeutics Formerly VC-backed San Diego, CA
Lexeo Therapeutics Formerly VC-backed New York, NY
NexImmune Formerly VC-backed Gaithersburg, MD
Galectin Therapeutics Corporation Norcross, GA
Nimbus Therapeutics Venture Capital-Backed Boston, MA
You’re viewing 5 of 98 competitors. Get the full list »

SpringWorks Therapeutics Patents

SpringWorks Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-12029711-B1 Dosage forms of mirdametinib Active 16-Mar-2023
US-20240307326-A1 Dosage forms of mirdametinib Pending 16-Mar-2023
US-20240307327-A1 Dosage forms of mirdametinib Pending 16-Mar-2023
US-20240358661-A1 Dosage forms of mirdametinib Pending 16-Mar-2023
US-20240122881-A1 Combination for use in treating cancers Pending 14-Oct-2022 A61K31/165
To view SpringWorks Therapeutics’s complete patent history, request access »

SpringWorks Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

SpringWorks Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore SpringWorks Therapeutics‘s full profile, request access.

Request a free trial

SpringWorks Therapeutics Investments (1)

SpringWorks Therapeutics’s most recent deal was a Joint Venture with MapKure. The deal was made on 18-Jun-2019.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
MapKure 18-Jun-2019 Joint Venture Drug Discovery
To view SpringWorks Therapeutics’s complete investments history, request access »

SpringWorks Therapeutics ESG

Risk Overview

Risk Rating

Updated October, 15, 2024

36.1 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,035

Rank

Percentile

Pharmaceuticals

Industry

of 847

Rank

Percentile

Pharmaceuticals

Subindustry

of 423

Rank

Percentile

To view SpringWorks Therapeutics’s complete esg history, request access »

SpringWorks Therapeutics FAQs

  • When was SpringWorks Therapeutics founded?

    SpringWorks Therapeutics was founded in 2017.

  • Where is SpringWorks Therapeutics headquartered?

    SpringWorks Therapeutics is headquartered in Stamford, CT.

  • What is the size of SpringWorks Therapeutics?

    SpringWorks Therapeutics has 305 total employees.

  • What industry is SpringWorks Therapeutics in?

    SpringWorks Therapeutics’s primary industry is Drug Discovery.

  • Is SpringWorks Therapeutics a private or public company?

    SpringWorks Therapeutics is a Public company.

  • What is SpringWorks Therapeutics’s stock symbol?

    The ticker symbol for SpringWorks Therapeutics is SWTX.

  • What is the current stock price of SpringWorks Therapeutics?

    As of 08-Nov-2024 the stock price of SpringWorks Therapeutics is $34.01.

  • What is the current market cap of SpringWorks Therapeutics?

    The current market capitalization of SpringWorks Therapeutics is $2.52B.

  • What is SpringWorks Therapeutics’s current revenue?

    The trailing twelve month revenue for SpringWorks Therapeutics is $86.2M.

  • Who are SpringWorks Therapeutics’s competitors?

    Travere Therapeutics, Lexeo Therapeutics, NexImmune, Galectin Therapeutics, and Nimbus Therapeutics are some of the 98 competitors of SpringWorks Therapeutics.

  • What is SpringWorks Therapeutics’s annual earnings per share (EPS)?

    SpringWorks Therapeutics’s EPS for 12 months was -$4.44.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »